Novo allocates as much as $2 billion for acquisitions

10/30/2008 | Bloomberg

Novo Nordisk is setting aside as much as $2 billion to fund potential takeovers of biotech firms in the coming 12 months, Chief Financial Officer Jesper Brandgaard announced. Of particular interest to the Danish drugmaker are companies specializing in diabetes and inflammatory disorders, Brandgaard said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY